Jesse Stawicki, DO
Internal Medicine · Mercerville, NJNPI 1497732598
Payments from drug & device makers
Across 1,075 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- AbbVie$2K
- Kowa Pharmaceuticals America, Inc.$2K
- Novo Nordisk$2K
- GSK$2K
- Lilly USA, LLC$2K
- plus $9K from 30 others
What the payments were for
- Food & beverage$22,720100%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 122 | $5,500 |
| AbbVie(2 entities) | 97 | $1,874 |
| Kowa Pharmaceuticals America, Inc. | 110 | $1,617 |
| Novo Nordisk | 111 | $1,611 |
| GSK | 68 | $1,560 |
| Lilly USA, LLC | 92 | $1,505 |
| Boehringer Ingelheim | 79 | $1,494 |
| Amgen | 37 | $1,270 |
| Amarin Pharma, Inc. | 55 | $1,033 |
| Pfizer | 53 | $1,009 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 75 | $871 |
| Bayer | 27 | $595 |
| Johnson & Johnson | 12 | $551 |
| Abbott | 15 | $265 |
| Merck | 20 | $257 |
| Idorsia Pharmaceuticals US Inc | 17 | $256 |
| Exact Sciences | 10 | $217 |
| Astellas Pharma US Inc | 12 | $184 |
| Novartis | 11 | $163 |
| E.r. Squibb & Sons, L.L.C. | 6 | $147 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Paratek Pharmaceuticals, Inc. | 8 | $115 |
| Sanofi Pasteur Inc. | 8 | $110 |
| Eisai Inc. | 5 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Esperion Therapeutics, Inc. | 3 | $45 |
| Phathom Pharmaceuticals, Inc. | 3 | $43 |
| IBSA Pharma Inc. | 3 | $42 |
| Hikma Pharmaceuticals USA | 3 | $35 |
| Nevro Corp. | 1 | $29 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
| Medicure Pharma Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Avion Pharmaceuticals | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,753 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 81 | $73,042 |
| FarxigaDapagliflozin Propanediol | 42 | $57,330 |
| JardianceEmpagliflozin | 38 | $52,639 |
| VascepaIcosapent Ethyl | 41 | $28,740 |
| OzempicSemaglutide | 25 | $28,582 |
| RybelsusSemaglutide | 25 | $28,470 |
| JanuviaSitagliptin Phosphate | 13 | $18,752 |
| XareltoRivaroxaban | 16 | $16,563 |
| Nateglinide | 146 | $12,062 |
| MyrbetriqMirabegron | 13 | $8,887 |
| Icosapent Ethyl | 25 | $6,989 |
| SynthroidLevothyroxine Sodium | 84 | $6,853 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,176 |
| Levothyroxine Sodium | 427 | $5,137 |
| Tiotropium Bromide | 13 | $5,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,009 | $73,04281 claims |
| AstraZenecaFarxiga, Symbicort | $5,500 | $60,09456 claims |
| Novo NordiskOzempic, Rybelsus | $1,611 | $57,05250 claims |
| Boehringer IngelheimJardiance | $1,494 | $52,63938 claims |
| MerckJanuvia | $257 | $18,75213 claims |
| Johnson & JohnsonXarelto | $551 | $16,56316 claims |
| Astellas Pharma US IncMyrbetriq | $184 | $8,88713 claims |
| AbbVieSynthroid | $1,874 | $6,85384 claims |
| GSKBreo Ellipta | $1,560 | $6,17617 claims |
| NovartisDiovan | $163 | $3,99712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Mercerville
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.